Marketdash
Back to News

Medicare Slashes Prices on 15 Drugs Including Wegovy and Ozempic to $274 Monthly

MarketDash Editorial Team
12 days ago
Medicare has negotiated lower prices on 15 high-cost medications, including Novo Nordisk's popular GLP-1 drugs, with changes taking effect in 2027 that could save enrollees $685 million annually in out-of-pocket costs.

The Centers for Medicare and Medicaid Services dropped some welcome news on Tuesday: it's secured significantly lower prices on 15 of its most expensive medications, with the new rates kicking in come 2027.

Big Price Cuts Coming for Weight-Loss Blockbusters

The headline grabber here is the $274 monthly price tag for Novo Nordisk's (NVO) semaglutide—the active ingredient in Wegovy, Ozempic, and Rybelsus. That's the same drug that's been dominating headlines and pharmacy bills alike, and now Medicare's getting a substantially better deal on it.

But the GLP-1 drugs aren't the only ones seeing cuts. AstraZeneca's (AZN) leukemia treatment Calquence, Boehringer's lung drug Ofev, and Pfizer's (PFE) breast cancer medication Ibrance all got whacked by 40-50% from their estimated net prices. That's real money for patients dealing with serious conditions.

The math on the savings is pretty compelling. When these negotiated prices take effect in 2027, Medicare enrollees should pocket around $685 million in out-of-pocket savings, while Medicare itself will save $12 billion. These negotiations are part of the broader Inflation Reduction Act that former President Joe Biden signed into law, expanding the government's ability to bargain on drug prices.

Timing Is Everything as Medicare Costs Climb

The announcement comes at an interesting moment. Medicare costs aren't exactly heading downward elsewhere—the standard monthly Part B premium is jumping 9.7% to $202.90 in 2026. So while these drug price cuts will help, seniors are still facing higher overall healthcare bills.

Meanwhile, the pharmaceutical industry is navigating intense pressure from the Trump Administration to bring drug prices down. Earlier this month, President Donald Trump announced a major deal with Eli Lilly (LLY) and Novo Nordisk to reduce prices and expand coverage for weight-loss medications like Zepbound and Wegovy. Starting April 2026, Medicare and Medicaid will cover obesity treatments including GLP-1 drugs, slashing patient costs to $50-$350 monthly instead of the current $1,000-plus price tags.

And Pfizer was actually first to the table, reaching a historic agreement with the Trump administration back in September to align U.S. drug prices with the lowest prices paid in other developed countries under the most-favored-nation policy.

The big picture? Drug pricing negotiations are accelerating, and patients should start seeing real relief in their wallets—though they'll need to wait until 2027 for most of these changes to materialize.

Back to News

Medicare Slashes Prices on 15 Drugs Including Wegovy and Ozempic to $274 Monthly

MarketDash Editorial Team
12 days ago
Medicare has negotiated lower prices on 15 high-cost medications, including Novo Nordisk's popular GLP-1 drugs, with changes taking effect in 2027 that could save enrollees $685 million annually in out-of-pocket costs.

The Centers for Medicare and Medicaid Services dropped some welcome news on Tuesday: it's secured significantly lower prices on 15 of its most expensive medications, with the new rates kicking in come 2027.

Big Price Cuts Coming for Weight-Loss Blockbusters

The headline grabber here is the $274 monthly price tag for Novo Nordisk's (NVO) semaglutide—the active ingredient in Wegovy, Ozempic, and Rybelsus. That's the same drug that's been dominating headlines and pharmacy bills alike, and now Medicare's getting a substantially better deal on it.

But the GLP-1 drugs aren't the only ones seeing cuts. AstraZeneca's (AZN) leukemia treatment Calquence, Boehringer's lung drug Ofev, and Pfizer's (PFE) breast cancer medication Ibrance all got whacked by 40-50% from their estimated net prices. That's real money for patients dealing with serious conditions.

The math on the savings is pretty compelling. When these negotiated prices take effect in 2027, Medicare enrollees should pocket around $685 million in out-of-pocket savings, while Medicare itself will save $12 billion. These negotiations are part of the broader Inflation Reduction Act that former President Joe Biden signed into law, expanding the government's ability to bargain on drug prices.

Timing Is Everything as Medicare Costs Climb

The announcement comes at an interesting moment. Medicare costs aren't exactly heading downward elsewhere—the standard monthly Part B premium is jumping 9.7% to $202.90 in 2026. So while these drug price cuts will help, seniors are still facing higher overall healthcare bills.

Meanwhile, the pharmaceutical industry is navigating intense pressure from the Trump Administration to bring drug prices down. Earlier this month, President Donald Trump announced a major deal with Eli Lilly (LLY) and Novo Nordisk to reduce prices and expand coverage for weight-loss medications like Zepbound and Wegovy. Starting April 2026, Medicare and Medicaid will cover obesity treatments including GLP-1 drugs, slashing patient costs to $50-$350 monthly instead of the current $1,000-plus price tags.

And Pfizer was actually first to the table, reaching a historic agreement with the Trump administration back in September to align U.S. drug prices with the lowest prices paid in other developed countries under the most-favored-nation policy.

The big picture? Drug pricing negotiations are accelerating, and patients should start seeing real relief in their wallets—though they'll need to wait until 2027 for most of these changes to materialize.